

AMENDMENTS TO THE CLAIMS UNDER REVISED 37 C.F.R. § 1.121

Please cancel Claims 33 and 53. Please amend the claims as follows:

1-38. (Canceled)

39. (Currently amended) ~~The A composition of claim 33~~ comprising:
_____ a) wherein the HIV infected cells that have been treated with Wydase® or a hyaluronidase enzyme with equivalent activity at a concentration of at least .01611 units/mL, and
b) optionally a pharmaceutically acceptable carrier or diluent.

40. (Currently amended) The composition of claim ~~33~~-39 wherein the HIV infected cells are human host cells.

41. (Previously presented) The composition of claim 40 wherein the HIV infected cells are human peripheral blood mononuclear cells or antigen presenting cells.

42. (Previously presented) The composition of claim 40 wherein the HIV infected cells exhibit reduced cell viability.

43. (Previously presented) The composition of claim 42 wherein the HIV infected cells form HIV immunogens.

44. (Previously presented) The composition of claim 43 wherein the immunogens prime and activate antigen presenting cells.

45. (Previously presented) The composition of claim 44 wherein the antigen presenting cells are macrophages, monocytes or both.

46. (Previously presented) The composition of claim 45 wherein the antigen presenting cells are capable of engendering an immune response that imparts to naïve cells resistance to HIV challenge.

47. (Previously presented) The composition of claim 45 wherein the antigen presenting cells are capable of transferring HIV immunity to naïve cells following co-incubation with the treated cells.

48. (Currently amended) A composition comprising:

- a) HIV infected cells that have been treated with hyaluronidase, and
- b) optionally a pharmaceutically acceptable carrier or diluent,

wherein the HIV infected cells have been treated with hyaluronidase for ~~more than~~ at least one two days.

49. (Currently amended) The composition of claim 48 wherein the HIV infected cells have been treated with hyaluronidase for ~~more than~~ at least six days.

50. (Previously presented) The composition of claim 48 wherein the HIV infected cells exhibit reduced cell viability.

51. (Currently amended) A composition comprising:

- a) HIV infected cells that have been treated with hyaluronidase, and
- b) optionally a pharmaceutically acceptable carrier or diluent,

wherein the HIV infected cells have been treated with Wydase® or a hyaluronidase enzyme with equivalent activity at a concentration of at least .01611 units/mL ~~have been treated with a toxic concentration of hyaluronidase for more than~~ at least one two days.

52. (Currently amended) The composition of claim 51 wherein the HIV infected cells have been treated with hyaluronidase for ~~more than~~ at least six days.

53. (Canceled)

54. (Previously presented) A composition comprising:

- a) HIV infected cells that have been treated with hyaluronidase, and

b) optionally a pharmaceutically acceptable carrier or diluent,
wherein the cells form HIV immunogens or antigens that prime and activate antigen presenting cells.

55. (Previously presented) The composition of claim 54 wherein the HIV infected cells are human host cells.

56. (Previously presented) The composition of claim 54 wherein the Antigen Presenting Cells are capable of engendering an immune response that imparts to naïve cells resistance to HIV challenge.

57. (Previously presented) A composition comprising:

- a) HIV infected cells that have been treated with hyaluronidase, and
 - b) optionally a pharmaceutically acceptable carrier or diluent,
- wherein the HIV infected cells exhibit reduced cell viability.

58. (Previously presented) The composition of claim 57 wherein the HIV infected cells form HIV immunogens.